Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp265 | Osteoporosis: pathophysiology and epidemiology | ECTS2014

High prevalence of vertebral fractures at time of screening for orthotopic liver transplantation

Krol Charlotte , Dekkers Olaf , Kroon Herman , Rabelink Ton , van Hoek Bart , Hamdy Neveen

Purpose: Osteoporosis and fractures are prevalent in orthotopic liver transplant (OLT) recipients but data on these skeletal complications are scarce in patients with end-stage liver disease awaiting liver transplantation. The aim of our study was to evaluate the prevalence of osteoporosis and vertebral fractures at screening for OLT, to determine risk factors for skeletal pathology and to evaluate the predictive value of BMD for fracture risk in these patients.<p class="a...

ba0003pp271 | Osteoporosis: pathophysiology and epidemiology | ECTS2014

Secondary causes for osteoporosis significantly contribute to fracture risk in patients with osteopenia and a recent fracture

Malgo Frank , Appelman-Dijkstra Natasha , Termaat Frank , van der Heide Huub , Schipper Inger , Hamdy Neveen

Introduction: The reported prevalence of secondary causes for osteoporosis in men and women aged ≥50 years with a fracture is 35–60%, but data on these causes are scarce in patients with osteopenia and fractures.Objective: To investigate whether secondary causes for osteoporosis are prevalent and may contribute to fracture risk in patients aged ≥50 years with osteopenia and a recent fracture.Materials and methods: ...

ba0003pp404 | Other diseases of bone and mineral metabolism | ECTS2014

Effects of up to 15 years of recombinant human GH replacement therapy on the skeleton in adult GH deficiency: the Leiden Cohort Study

Appelman-Dijkstra Natasha , Claessen Kim , Hamdy Neveen , Pereira Alberto , Biermasz Nienke

Background: Adult GH Deficiency (GHD) is associated with decreased bone mass and increased fracture risk. Recombinant human GH (rhGH) replacement therapy leads to progressive increases in bone mineral density (BMD) for up to 7 years of treatment, but little is known on longer term effects of rhGH therapy on bone mass or fracture risk.Methods: 230 GHD patients (mean age 47.1 years, 52.6% female) on rhGH replacement therapy for ≥5 years were included...

ba0005p35 | Bone biomechanics and quality | ECTS2016

Bone material properties as measured by Reference Point Indentation are low in subjects with acromegaly

Malgo Frank , Hamdy Neveen A T , Pereira Alberto M , Biermasz Nienke R , Appelman-Dijkstra Natasha M

Introduction: Acromegaly is a rare disease caused by excess growth hormone (GH) production by an adenoma of the anterior pituitary gland. The skeletal complications of GH and IGF-1 excess include increased bone turnover, increased cortical bone mass and deteriorated microarchitecture of trabecular bone, associated with a high risk of vertebral fractures in the presence of a relatively normal Bone Mineral Density (BMD). There are no data on bone material properties in patients ...

ba0005p464 | Other diseases of bone and mineral metabolism | ECTS2016

The course and management of craniofacial fibrous dysplasia: a case series

Majoor Bas , Appelman-Dijkstra Natasha , Bruggemann Jens , van de Sande Michiel , Dijkstra Sander , Hamdy Neveen

Introduction: Cranialfacial fibrous dysplasia (CFD) presents with pain, facial asymmetry and/or neurological complications. It has been suggested that patients with CFD respond favourably to treatment with bisphosphonates, by a decrease in pain and arrest of progression. Therefore, we performed a retrospective study of 56 patients with CFD in our center.Methods: We assessed clinical characteristics and disease course. Furthermore, clinical and biochemica...

ba0007p222 | (1) | ICCBH2019

Long-term clinical outcome in chronic recurrent multifocal osteomyelitis (CRMO): the Leiden cohort

Ramautar Ashna IE , Hamdy Neveen AT , Hissink-Muller Petra CE , Cate Rebecca ten , Appelman-Dijkstra Natasha M

Objectives: To characterize clinical features and long-term outcome of CRMO, a rare inflammatory bone disease of childhood and adolescence, which forms part of the spectrum of chronic non-bacterial osteomyelitis (CNO).Methods: We studied 33 patients with an established diagnosis of CRMO followed at the Centre for Bone Quality of the Leiden University Medical Center from 1994 to 2018. Demographic and clinical data were collected at presentation and last f...